Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2025-07-07 00:00:00 ET · period of report 2025-07-02 · accession 0000914475-25-000149 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-07 | 2025-07-02 | NBIX | Onyia Jude | CSO | M - OptEx | $84.74 | +20.4K | 38.7K | +111% | +$1.73M |
| D | 2025-07-07 | 2025-07-02 | NBIX | Onyia Jude | CSO | S - Sale+OE | $130.13 | -20.4K | 18.3K | -53% | -$2.65M |
| D | 2025-07-07 | 2025-07-02 | NBIX | Onyia Jude | CSO | M - OptEx | $0.00 | -20.4K | 95.1K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-02 | M | A | 20,362 | $84.74 | 38,651 | D | — | — | |
| 2 | Common | Common Stock | 2025-07-02 | S | D | 20,362 | $130.13 | 18,289 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) Includes an aggregate of 200 shares purchased on February 28, 2025, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 3 | Derivative | Non-Qualified Stock Option | 2025-07-02 | M | D | 20,362 | $0.00 | 95,087 | D | $84.74 · — to 2031-11-29 | 20,362 Common Stock | (F4) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. These options will expire ten years from the date of grant on November 29, 2031. |